BR201 – rare opportunity in preventing post-surgery adhesion

Adhesions are associated with serious complications, including higher risk of morbidity and mortality.

With increased hospitalisation timings, longer operative times, and longer length of hospital stay, post-surgical adhesions pose a great financial burden.

We have a product candidate, BR201, as a solution helping to prevent adhesions post surgery.

BR201 acts as a protective barrier and it has already demonstrated efficacy in clinical practical tests performed.

Working with an undisclosed but highly respected medical university, a clinical test with a small group of volunteer patients was conducted. The tests results were highly encouraging .

Branson Pharma find this business opportunity highly attractive due to 

- The fact, there are no solutions available to prevent adhesions

- Extremely high interest amongst surgeons in this field

- The molecule is scalable for a commercial level production 

- Molecule costs – low

- Molecule well established use in other indications and a possibility to capitilise on this science

- Low investment and low risks

Strategy is based on reformulations of established drugs for the US FDA 505(b)(2) regulatory pathway.

Similar approach is developed to the EU registration: either via a well established use application or via a newly established repurpusing framework by EMA.